Trial | NCT03448705  Report issue

Title

Safety of 4Fluart ID Suspension for Injection in Adult Subjects
A Phase I, Open-label to the Route of Administration, Single-blind to the ID Doses, Randomised, Active-controlled, Parallel Study to Evaluate the Safe Usability of 4Fluart ID Suspension for Injection in Adult Subjects

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    36
The primary objective of the study is to evaluate the safe usability of the study drugs, i.e. 4Fluart ID 1 µg haemagglutinin (HA)/0.1 ml QIV and 4Fluart ID 2 µg haemagglutinin (HA)/0.1 ml QIV in terms of safety concerns emerged.

The secondary objective of the study is to further assess safety in terms of safety parameters, as well as to assess the immunogenicity of 4Fluart ID 1 µg haemagglutinin (HA)/0.1 ml QIV and 4Fluart ID 2 µg haemagglutinin (HA)/0.1 ml QIV in terms of immunogenicity parameters.
Healthy volunteers (male and female) aged 18-59 years were enrolled into the study by signing subject information leaflet and informed consent form. After screening them, subjects complying with inclusion and exclusion criteria were included in the study, randomised and vaccinated with one of the investigational medicinal products assigned by the randomisation list.

Subjects were observed for thirty (30) minutes after vaccination for any immediate reactions. All adverse events (AEs) were collected from the enrolment to Day 21-28. Safety data between Day 0 and Day 7-9 were documented on a Diary card by each subject. Safety assessment were performed based on Day 7-9 and Day 21-28 safety data compared to the baseline on Day 0.

Blood samples for immunogenicity assays were collected immediately before vaccination on Day 0 (pre-vaccination blood samples) and on Day 21-28 (post-vaccination blood samples) in all subjects included in the study and complying with the study procedures. Immunogenicity were evaluated by hemagglutinin inhibition test in order to assess immune response 3-4 weeks after vaccination.

The assessment of safety and immunogenicity of 4Fluart ID 1 µg/0.1 ml QIV and 4Fluart ID 2 µg/0.1 ml QIV was performed in comparison to the authorised 3Fluart, i.e. 3Fluart intramuscular (IM) 6 µg/0.5 ml TIV.
Study Started
Jan 31
2018
Primary Completion
Apr 03
2018
Study Completion
Apr 03
2018
Last Update
Mar 03
2021

Biological 4Fluart ID suspension for injection study drug 1 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted)

Route of administration: intradermal, Dosage: 1 μg HA/strain / 0.1 ml, Package: 0.5 ml in one ampoule from which 0.1 ml is equal to a single dose, Dosage regimen: 1 x 0.1 ml, Treatment duration: single dose.

  • Other names: 4Fluart ID suspension for injection study drug, 4Fluart ID 1 µg/0.1 ml QIV

Biological 4Fluart ID suspension for injection study drug 2 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted)

Route of administration: intradermal, Dosage: 2 μg HA/strain / 0.1 ml, Package: 0.5 ml in one ampoule from which 0.1 ml is equal to a single dose, Dosage regimen: 1 x 0.1 ml, Treatment duration: single dose.

  • Other names: 4Fluart ID suspension for injection study drug, 4Fluart ID 2 µg/0.1 ml QIV

Biological 3Fluart suspension for injection, influenza vaccine (whole virion, inactivated, adjuvanted)

Route of administration: intramuscular, Dosage: 6 μg HA/strain / 0.5 ml, Package: 0.5 ml in one ampoule from which a total of 0.5 ml is equal to a single dose, Dosage regimen: 1 x 0.5 ml, Treatment duration: single dose.

  • Other names: 3Fluart suspension for injection, 3Fluart IM 6 µg/0.5 ml TIV

Group 1 - Study drug 1 (i.e. 4Fluart ID 1 µg/0.1 ml QIV) Experimental

Vaccination of 12 subjects will be performed with the intradermal quadrivalent influenza vaccine containing 1 µg haemagglutinin per virus strain in 0.1 ml as a single dose.

Group 2 - Study drug 2 (i.e. 4Fluart ID 2 µg/0.1 ml QIV) Experimental

Vaccination of 12 subjects will be performed with the intradermal quadrivalent influenza vaccine containing 2 µg haemagglutinin per virus strain in 0.1 ml as a single dose.

Group 3 - Comparator drug (i.e. 3Fluart IM 6 µg/0.5 ml TIV) Active Comparator

Vaccination of 12 subjects will be performed with the intramuscular trivalent influenza vaccine containing 6 µg haemagglutinin per virus strain in 0.5 ml as a single dose.

Criteria 

Inclusion Criteria:

Adult persons aged 18 to 59 years, determined on the day of enrolment from both sexes, mentally competent;
Good health (as determined by vital signs and existing medical condition) or stable medical condition. Subjects will not be excluded with known adequately treated clinically significant organ or systemic diseases (e.g. asthma or insulin treated), the significance of which, in the opinion of the investigator, will not compromise the subject's participation in the study;
Female volunteers of childbearing potential upon the decision of the investigator with a negative result from the urine pregnancy test prior to vaccination who agrees to use an acceptable contraception method or abstinence throughout the trial and to not become pregnant for the duration of the study;
Capability of participants to understand and comply with planned study procedures;
Participants provide written informed consent prior to initiation of study procedures;
Absence of any exclusion criteria.

Exclusion Criteria:

Pregnancy, breast feeding or positive urine pregnancy test at baseline prior to vaccination. Female subjects who are able to bear children but not willing to use an acceptable contraception method for the duration of the study. Pregnancy with regard to the total duration of the study.
Hypersensitivity to the active substances or to any of the excipients, such as thiomersal, or any component that may be present in traces, such as egg (ovalbumin), formaldehyde, gentamicin, neomycin, vancomycin or ciprofloxacin determined prior to vaccination;
Serious complications in the medical history with regard to any previous vaccination: encephalitis/encephalopathy, nonfebrile seizures, Guillain-Barré syndrome, vasculitis, neuritis, facial paresis determined prior to vaccination;
History of neurological symptoms or signs, or anaphylactic shock following administration of any vaccine determined prior to vaccination;
Serious disease, such as cancer, autoimmune disease, advanced arteriosclerotic disease, complicated diabetes mellitus, acute or progressive hepatic disease, acute or progressive renal disease, congestive heart failure with regard to the total duration of the study;
Immunosuppressive therapy within 36 months prior to vaccination and with regard to the total duration of the study;
Concomitant corticosteroid therapy, including high-dose inhaled corticosteroids with regard to the total duration of the study;
Receipt of immunostimulants with regard to the total duration of the study;
Receipt of parenteral immunoglobulin, blood products and/or plasma derivate within 3 months prior to vaccination and with regard to the total duration of the study;
Suspected or known HIV, Hepatitis-B virus (HBV) or Hepatitis-C virus (HCV) infection with regard to the total duration of the study;
Acute disease and/or axillary temperature ≥37oC within 3 days prior to vaccination;
Vaccine therapy within 4 weeks prior to vaccination and with regard to the total duration of the study;
Influenza vaccination (any kind) within 6 months prior to vaccination and with regard to the total duration of the study;
Experimental drug therapy within 4 weeks prior to vaccination and with regard to the total duration of the study;
Concomitant participation in another clinical study;
Any condition which, may interfere with the evaluation of the study (including major protocol deviation with regard to the total duration of the study);
Past or current psychiatric disease of the volunteer that upon judgement of the investigator may have an effect on the objective decision-making of the volunteer;
Alcohol or drug abuse of the participant.
No Results Posted